摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

ethyl 2,4-dioxo-5-phenoxypentanoate | 856256-81-0

中文名称
——
中文别名
——
英文名称
ethyl 2,4-dioxo-5-phenoxypentanoate
英文别名
2,4-dioxo-5-phenoxypentanoic acid ethyl ester;2,4-Dioxo-5-phenoxy-pentanoic acid ethyl ester
ethyl 2,4-dioxo-5-phenoxypentanoate化学式
CAS
856256-81-0
化学式
C13H14O5
mdl
——
分子量
250.251
InChiKey
RCUCLUKBIBGDHT-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.9
  • 重原子数:
    18
  • 可旋转键数:
    8
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.31
  • 拓扑面积:
    69.7
  • 氢给体数:
    0
  • 氢受体数:
    5

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Discovery and SAR of a novel series of metabotropic glutamate receptor 5 positive allosteric modulators with high ligand efficiency
    摘要:
    We report the optimization of a series of novel metabotropic glutamate receptor 5 (mGlu(5)) positive allosteric modulators (PAMs) from a 5,6-bicyclic class of dihydropyrazolo[1,5-a]pyridin-4(5H)-ones containing a phenoxymethyl linker. Studies focused on a survey of non-amide containing hydrogen bond accepting (HBA) pharmacophore replacements. A highly potent and selective PAM, 2-(phenoxymethyl)6,7-dihydropyrazolo[1,5-a]pyridin-4(5H)-one (11, VU0462054), bearing a simple ketone moiety, was identified (LE = 0.52, LELP = 3.2). In addition, hydroxyl, difluoro, ether, and amino variations were examined. Despite promising lead properties and exploration of alternative core heterocycles, linkers, and ketone replacements, oxidative metabolism and in vivo clearance remained problematic for the series. (C) 2014 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2014.04.087
  • 作为产物:
    描述:
    苯氧基丙酮草酸二乙酯乙醇sodium盐酸 作用下, 以 为溶剂, 以54%的产率得到ethyl 2,4-dioxo-5-phenoxypentanoate
    参考文献:
    名称:
    [EN] BICYCLIC TRIAZOLE AND PYRAZOLE LACTAMS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS
    [FR] UTILISATION DE LACTAMES DE TRIAZOLE ET DE PYRAZOLE BICYCLIQUES COMME MODULATEURS ALLOSTÉRIQUES DES RÉCEPTEURS MGLUR5
    摘要:
    在一个方面,该发明涉及到双环三唑和吡唑内酰胺,它们的衍生物以及相关化合物,这些化合物可用作代谢型谷氨酸受体亚型5(mGluR5)的正向变构调节剂;制备这些化合物的合成方法;包含这些化合物的药物组合物;以及使用这些化合物和组合物治疗与谷氨酸功能障碍相关的神经和精神疾病的方法。本摘要旨在作为在特定领域进行搜索的扫描工具,并不意味着对本发明的限制。
    公开号:
    WO2012083224A1
点击查看最新优质反应信息

文献信息

  • [EN] SUBSTITUTED BICYCLIC ARALKYL PYRAZOLE LACTAM ANALOGS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS<br/>[FR] ANALOGUES D'ARALKYL PYRAZOLE LACTAME BICYCLIQUES SUBSTITUÉS EN TANT QUE MODULATEURS ALLOSTÉRIQUES DES RÉCEPTEURS MGLUR5
    申请人:UNIV VANDERBILT
    公开号:WO2013192350A1
    公开(公告)日:2013-12-27
    In one aspect, the invention relates to substituted bicyclic aralkyl pyrazole lactam analogs, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    在一个方面,该发明涉及替代的双环芳基吡唑内酰胺类似物,其衍生物以及相关化合物,这些化合物可用作代谢型谷氨酸受体亚型5(mGluR5)的正向变构调节剂;制备这些化合物的合成方法;包括这些化合物的药物组合物;以及使用这些化合物和组合物治疗与谷氨酸功能障碍相关的神经和精神疾病的方法。本摘要旨在作为在特定领域进行搜索的扫描工具,并不打算限制本发明。
  • [EN] SUBSTITUTED BICYCLIC CYCLOALKYL PYRAZOLE LACTAM ANALOGS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS<br/>[FR] ANALOGUES DE LACTAME DE PYRAZOLE DE CYCLOALKYLE BICYCLIQUES SUBSTITUÉS EN TANT QUE MODULATEURS ALLOSTÉRIQUES DES RÉCEPTEURS MGLUR5
    申请人:UNIV VANDERBILT
    公开号:WO2013192347A1
    公开(公告)日:2013-12-27
    In one aspect, the invention relates to substituted bicyclic cycloalkyl pyrazole lactam analogs, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    在一个方面,该发明涉及替代的双环环烷基吡唑内酰胺类似物,其衍生物和相关化合物,这些化合物可用作代谢型谷氨酸受体亚型5(mGluR5)的阳性变构调节剂;制备这些化合物的合成方法;含有这些化合物的药物组合物;以及使用这些化合物和组合物治疗与谷氨酸功能障碍相关的神经和精神疾病的方法。本摘要旨在作为在特定领域进行搜索的扫描工具,并不意味着对本发明的限制。
  • [EN] BICYCLIC PYRAZOLE COMPOUNDS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS<br/>[FR] UTILISATION DE COMPOSÉS BICYCLIQUES DE PYRAZOLE EN TANT QUE MODULATEURS ALLOSTÉRIQUES DES RÉCEPTEURS MGLUR5
    申请人:UNIV VANDERBILT
    公开号:WO2012078817A1
    公开(公告)日:2012-06-14
    In one aspect, the invention relates to bicyclic pyrazole compounds, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    在一个方面,这项发明涉及到双环吡唑化合物、其衍生物和相关化合物,这些化合物可作为代谢型谷氨酸受体亚型5(mGluR5)的正向变构调节剂;制备这些化合物的合成方法;包括这些化合物的药物组合物;以及使用这些化合物和组合物治疗与谷氨酸功能障碍相关的神经和精神疾病的方法。这个摘要旨在作为在特定领域进行搜索的扫描工具,并不意味着对本发明的限制。
  • Pyrrole and pyrazole DAAO inhibitors
    申请人:Fang Kevin Q.
    公开号:US20050143443A1
    公开(公告)日:2005-06-30
    Methods for increasing D-Serine concentration and reducing concentration of the toxic products of D-Serine oxidation, for enhancing learning, memory and/or cognition, or for treating schizophrenia, Alzheimer's disease, ataxia or neuropathic pain, or preventing loss in neuronal function characteristic of neurodegenerative diseases involve administering to a subject in need of treatment a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof: wherein R 1 and R 2 are independently selected from hydrogen, halo, nitro, alkyl, acyl, alkylaryl, and XYR 5 ; or R 1 and R 2 , taken together, form a 5, 6, 7 or 8-membered substituted or unsubstituted carbocyclic or heterocyclic group; X and Y are independently selected from O, S, NH, and (CR 6 R 7 ) n ; R 3 is hydrogen, alkyl or M + ; M is aluminum, calcium, lithium, magnesium, potassium, sodium, zinc ion or a mixture thereof; Z is N or CR 4 ; R 4 is from selected from hydrogen, halo, nitro, alkyl, alkylaryl, and XYR 5 ; R 5 is selected from aryl, substituted aryl, heteroaryl and substituted heteroaryl; R 6 and R 7 are independently selected from hydrogen and alkyl; n is an integer from 1 to 6; at least one of R 1 , R 2 and R 4 is other than hydrogen; and at least one of X and Y is (CR 6 R 7 ) n . D-serine or cycloserine may be coadministered along with the compound of formula I.
    增加D-丝氨酸浓度和减少D-丝氨酸氧化的有毒产物浓度的方法,用于增强学习、记忆和/或认知能力,或用于治疗精神分裂症、阿尔茨海默病、共济失调或神经病性疼痛,或预防神经元功能丧失,这涉及向需要治疗的受试者施用化合物I的治疗有效量,或其药学上可接受的盐或溶剂:其中R1和R2独立地选自氢、卤素、硝基、烷基、酰基、烷基芳基和XYR5;或R1和R2共同形成一个5、6、7或8-成员的取代或未取代的碳环或杂环基团;X和Y独立地选自O、S、NH和(CR6R7)n;R3为氢、烷基或M+;M为铝、钙、锂、镁、钾、钠、锌离子或其混合物;Z为N或CR4;R4选自氢、卤素、硝基、烷基、烷基芳基和XYR5;R5选自芳基、取代芳基、杂环芳基和取代杂环芳基;R6和R7独立地选自氢和烷基;n为1到6的整数;R1、R2和R4中至少有一个不是氢;X和Y中至少有一个是(CR6R7)n。 D-丝氨酸或环丝氨酸可以与化合物I的共同给药。
  • Pyrrole and Pyrazole DAAO Inhibitors
    申请人:Fang Q. Kevin
    公开号:US20100016397A1
    公开(公告)日:2010-01-21
    Methods for increasing D-Serine concentration and reducing concentration of the toxic products of D-Serine oxidation, for enhancing learning, memory and/or cognition, or for treating schizophrenia, Alzheimer's disease, ataxia or neuropathic pain, or preventing loss in neuronal function characteristic of neurodegenerative diseases involve administering to a subject in need of treatment a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof: wherein R 1 and R 2 are independently selected from hydrogen, halo, nitro, alkyl, acyl, alkylaryl, and XYR 5 ; or R 1 and R 2 , taken together, form a 5, 6, 7 or 8-membered substituted or unsubstituted carbocyclic or heterocyclic group; X and Y are independently selected from O, S, NH, and (CR 6 R 7 ) n ; R 3 is hydrogen, alkyl or M + ; M is aluminum, calcium, lithium, magnesium, potassium, sodium, zinc ion or a mixture thereof; Z is N or CR 4 ; R 4 is from selected from hydrogen, halo, nitro, alkyl, alkylaryl, and XYR 5 ; R 5 is selected from aryl, substituted aryl, heteroaryl and substituted heteroaryl; R 6 and R 7 are independently selected from hydrogen and alkyl; n is an integer from 1 to 6; at least one of R 1 , R 2 and R 4 is other than hydrogen; and at least one of X and Y is (CR 6 R 7 ) n . D-serine or cycloserine may be coadministered along with the compound of formula I.
    增加D-丝氨酸浓度并减少D-丝氨酸氧化产物浓度的方法,以增强学习、记忆和/或认知能力,或治疗精神分裂症、阿尔茨海默病、共济失调或神经病理性疼痛,或预防神经退行性疾病特征性神经元功能损失,包括向需要治疗的受试者施用公式I的化合物或其药学上可接受的盐或溶剂的治疗有效量:其中,R1和R2分别选自氢、卤素、硝基、烷基、酰基、烷基芳基和XYR5;或R1和R2共同形成5、6、7或8成员取代或未取代的碳环或杂环基;X和Y分别选自O、S、NH和(CR6R7)n;R3为氢、烷基或M+;M为铝离子、钙离子、锂离子、镁离子、钾离子、钠离子、锌离子或其混合物;Z为N或CR4;R4选自氢、卤素、硝基、烷基、烷基芳基和XYR5;R5选自芳基、取代芳基、杂芳基和取代杂芳基;R6和R7分别选自氢和烷基;n为1到6的整数;R1、R2和R4中至少有一个不是氢;X和Y中至少有一个是(CR6R7)n。D-丝氨酸或环丝氨酸可以与公式I的化合物一起共同施用。
查看更多